Idera Pharmaceuticals (IDRA) and Merck (MRK) Extend Research Collaboration for 1-Yr
More News related to IDRA
- Idera Pharma (IDRA) Posts Break-Even Q3 EPS, Down 8c from Q308
- Idera Pharma (IDRA) Presents IMO-2125 Preclinical Data
- Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
- Idera Pharma (IDRA) Announces TLR Patent Issuance
- Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use
More News related to MRK
- Photos: 'Project Runway' Designer Launches New Video in Online Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma
- Hapoalim Securities Initiates Coverage on Merck (MRK) with a Hold; Vytorin and Zetia Headwinds
- Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology
- Leerink Swann Upgrades Merck & Co (MRK) to Outperform; Near-Term Risks Already Factored In
- D.C. Vaccine Conference Attracts Government Policy Makers and Biotech Innovators
More News related to Corporate News
- AMD CFO Says Balance Sheet is 'Main Priority', Believes Gross Margin Can Be 45%+ Over the Long-Term
- Highlights From CLWR's Q3 Conference Call: Funding Initiative A Go!, But Investors Worry About Long-Term Outlook
- S&P Raises Red Hat's (RHT) Corporate Credit Rating to 'BB+'
- Hemispherx (HEB) Shares Tumble Amid Class Action Lawsuit by Shareholders
- Sypris Solutions (SYPR) Sibsidiary Awarded $200M 5-Year IDIQ Contract from U.S. DoD to Replace KYK-13
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Merck & Co., Inc. (NYSE: MRK) has extended its research collaboration with Idera for an additional year. The Company and Merck entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the Company's investigational agonist compounds targeting Toll-like Receptors 7, 8, and 9 in the fields of oncology, infectious diseases and Alzheimer's disease in December 2006. As part of the agreement, the two companies engaged in a two-year research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields.
Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of DNA- and RNA-based compounds for the treatment of infectious diseases, autoimmune diseases, cancer, and asthma and allergies and for use as vaccine adjuvants.
Related Categories
Corporate NewsStocks Mentioned
+0.18
-0.42Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
